Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 32mg - modified release tablet - 32 mg - active: hydromorphone hydrochloride 32mg excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black iron oxide yellow macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry white y-30-18037 polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

Canada - engleză - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 10mg - hydromorphone hydrochloride 10mg - opiate agonists

Canada - engleză - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 100mg - hydromorphone hydrochloride 100mg - opiate agonists

Canada - engleză - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 50mg - hydromorphone hydrochloride 50mg - opiate agonists

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] significant respiratory depression [see warnings and precautions (5.7)] -

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2 ) ],   reserve hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.7)] - known or suspected gastrointestinal obstruction, including paralytic ileus [se

Australia - engleză - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - hydromorphone-hameln and hydromorphone-hameln-hp injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium citrate dihydrate; sodium hydroxide; hydrochloric acid; sodium chloride - hydromorphone-hameln and hydromorphone-hameln-hp injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Canada - engleză - Health Canada

teva canada limited - hydromorphone hydrochloride - tablet - 2mg - hydromorphone hydrochloride 2mg - opiate agonists

Australia - engleză - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.